Pathway flux analysis at a genome-scale for the prediction of response to the immune checkpoint therapy in patients with melanoma
Latest Information Update: 11 Jun 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
Most Recent Events
- 11 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology